gefitinib has been researched along with Acute Myelogenous Leukemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C | 1 |
| Amrein, PC; Berchuck, J; Deangelo, DJ; Galinsky, I; Golub, T; Neuberg, D; Sirulnik, LA; Stegmaier, K; Stone, RM; Wadleigh, M | 1 |
| Chakravarti, B; Chattopadhyay, N; Datta, D; Dogra, S; Gurjar, A; Kumar, H; Kushwaha, S; Rao, G; Sanyal, S; Singh, AK; Tripathi, AK; Trivedi, AK; Vishwakarma, AL; Yadav, M; Yadav, PN | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Aleskog, A; Danielsson, K; Eriksson, A; Grundmark, B; Henriksson, R; Höglund, M; Larsson, R; Lindhagen, E; Nygren, P; Wickström, M | 1 |
| Downing, JR | 1 |
| Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
| Daub, H; Schreiber, TB; Weber, C | 1 |
| Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S | 1 |
| Corsello, SM; Deangelo, DJ; Golub, TR; Ross, KN; Stegmaier, K; Wong, JS | 1 |
| Duan, R; Grandis, JR; Johnson, DE; Jones, JE; Miranda, MB; Redner, RL; Thomas, SM | 1 |
1 trial(s) available for gefitinib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Treatment Failure | 2014 |
11 other study(ies) available for gefitinib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger | 2023 |
Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; ErbB Receptors; Gefitinib; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H2; Receptors, Histamine H4 | 2016 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Caspase 3; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Immunochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Tumor Cells, Cultured | 2008 |
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2012 |
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines | 2012 |
Gefitinib induces myeloid differentiation of acute myeloid leukemia.
Topics: Biomarkers, Tumor; Cell Differentiation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tumor Cells, Cultured | 2005 |
Gefitinib potentiates myeloid cell differentiation by ATRA.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Drug Synergism; Gefitinib; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tretinoin | 2008 |